The VLVbio K18 assays in Drug Discovery
K18 IN DRUG DISCOVERY K18 IN DRUG DISCOVERY K18 IN DRUG DISCOVERY K18 IN DRUG DISCOVERY K18 IN DRUG DISCOVERY
Screening of Anticancer Agents
Screening of Anticancer Agents in 2D and 3D cell cultures
In the early phases of the discovery of new anticancer compounds, studying the efficacy of the compounds on two-dimensional (2D) or three-dimensional (3D) cell cultures are cost-effective and commonly used methods. When using 2D cell cultures, the M30® ELISAs and the M65® ELISA provide information regarding the mode of cell death (necrosis or apoptosis) and are of value when studying the efficacy of compounds on tumour cells in drug discovery. In studies using 3D cell cultures and spheroids, the M30® ELISAs are efficient in measuring apoptotic cell death and in the identification of compounds inducing apoptosis.
Studies on 2D and 3D cell cultures
The M30® ELISAs and M65® ELISA in studies on 2D and 3D cell cultures
The M30® ELISAs and the M65® ELISA describe the relative contribution of apoptosis and necrosis
The M30® ELISAs and the M65® ELISA only require measurements at a single, specific time point, as they measure the accumulation of intact and cleaved K18
The M30® ELISAs and the M65® ELISA can also be used when examining time-kinetics and dose-response relationships
The M30® ELISAs enable accurate identification ofcompounds that induce apoptosis, a major target of anticancer drugs